The Accuracy of Technetium-99 m Pyrophosphate Imaging in Diagnosing Transthyretin Cardiac Amyloidosis and Its Impact on Patient Management

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Date 2025 Jan 23

PMID 39847173

Authors

Zainab Altaha

Robert J H Miller

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review evaluates recent advancements in Technetium-99 m pyrophosphate (99mTc-PYP) imaging for transthyretin amyloid cardiomyopathy (ATTR-CM). We summarize the advantages of single-photon emission computed tomography (SPECT) over planar imaging, the potential impact of quantitative methods, and emerging data for quantifying response to therapy.

Recent Findings: The current literature demonstrates the superior diagnostic accuracy of SPECT compared with planar imaging in 99mTc-PYP studies. Emerging quantitative methods, using hybrid SPECT/CT and artificial intelligence, show promise for enhancing diagnostic precision and risk assessment. Recent studies have also highlighted the potential of 99mTc-PYP quantification for monitoring treatment response. 99mTc-PYP SPECT imaging has exceptional diagnostic accuracy for ATTR-CM. Quantitative techniques, which can be facilitated by artificial intelligence, improve risk stratification and may aid in treatment monitoring. Future research should focus on clarifying the clinical role and optimal approach for quantification.

References

Fine N, Davis M, Anderson K, Delgado D, Giraldeau G, Kitchlu A . Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. Can J Cardiol. 2020; 36(3):322-334. DOI: 10.1016/j.cjca.2019.12.034. View

Kittleson M, Ruberg F, Ambardekar A, Brannagan T, Cheng R, Clarke J . 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023; 81(11):1076-1126. DOI: 10.1016/j.jacc.2022.11.022. View

Ladefoged B, Dybro A, Povlsen J, Vase H, Clemmensen T, Hvitfeldt Poulsen S . Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge. Int J Cardiol. 2020; 304:138-143. DOI: 10.1016/j.ijcard.2019.12.063. View

Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A . Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133(24):2404-12. DOI: 10.1161/CIRCULATIONAHA.116.021612. View

Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer M . (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013; 6(2):195-201. PMC: 3727049. DOI: 10.1161/CIRCIMAGING.112.000132. View

Poterucha T, Elias P, Bokhari S, Einstein A, DeLuca A, Kinkhabwala M . Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution. JACC Cardiovasc Imaging. 2020; 14(6):1221-1231. PMC: 8113330. DOI: 10.1016/j.jcmg.2020.08.027. View

Masri A, Bukhari S, Ahmad S, Nieves R, Eisele Y, Follansbee W . Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Cardiovasc Imaging. 2020; 13(2):e010249. PMC: 7032611. DOI: 10.1161/CIRCIMAGING.119.010249. View

Sperry B, Burgett E, Bybee K, McGhie A, OKeefe J, Saeed I . Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT/CT. J Nucl Cardiol. 2020; 27(5):1802-1807. DOI: 10.1007/s12350-020-02139-8. View

Stats M, Stone J . Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol. 2016; 25(5):413-7. DOI: 10.1016/j.carpath.2016.07.001. View

10.

Thelander U, Westermark G, Antoni G, Estrada S, Zancanaro A, Ihse E . Cardiac microcalcifications in transthyretin (ATTR) amyloidosis. Int J Cardiol. 2022; 352:84-91. DOI: 10.1016/j.ijcard.2022.01.036. View

11.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk R, Ferrari V . Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2021; 28(4):1769-1774. DOI: 10.1007/s12350-020-02455-z. View

12.

Sperry B, Bateman T, Akin E, Bravo P, Chen W, Dilsizian V . Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM. J Nucl Cardiol. 2022; 30(2):626-652. DOI: 10.1007/s12350-022-02985-8. View

13.

Chen W, Ton V, Dilsizian V . Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction. Curr Cardiol Rep. 2018; 20(4):23. DOI: 10.1007/s11886-018-0970-2. View

14.

Ahluwalia N, Roshankar G, Draycott L, Jimenez-Zepeda V, Fine N, Chan D . Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis. J Nucl Cardiol. 2023; 30(6):2464-2476. DOI: 10.1007/s12350-023-03297-1. View

15.

Hussain M, Krywanczyk A, Donnellan E, Martyn T, Hassan O, Alkharabsheh S . Association Between Atrial Uptake on Cardiac Scintigraphy With Technetium-99m-Pyrophosphate Labeled Bone-Seeking Tracers and Atrial Fibrillation. Circ Cardiovasc Imaging. 2022; 15(5):e013829. DOI: 10.1161/CIRCIMAGING.121.013829. View

16.

Donnellan E, Hussain M, Jaber W, Patel D, Kanj M, Wazni O . Atrial Uptake of Technetium-99m-Pyrophosphate Labeled Bone-Seeking Tracers Is Associated With Post Ablation Atrial Fibrillation Recurrence. JACC Clin Electrophysiol. 2022; 8(2):251-253. DOI: 10.1016/j.jacep.2021.11.016. View

17.

Porcari A, Fontana M, Canepa M, Biagini E, Cappelli F, Gagliardi C . Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy. Circulation. 2024; 149(15):1157-1168. PMC: 11000629. DOI: 10.1161/CIRCULATIONAHA.123.066524. View

18.

Sperry B, Vranian M, Tower-Rader A, Hachamovitch R, Hanna M, Brunken R . Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality. JACC Cardiovasc Imaging. 2017; 11(2 Pt 1):234-242. DOI: 10.1016/j.jcmg.2017.06.020. View

19.

Akincioglu C, Murthi M, Romsa J, Warrington J, Malhotra S . Comparison of cardio-focal and chest reconstruction of technetium-99m pyrophosphate scintigraphy for diagnosis of transthyretin cardiac amyloidosis: a quality assurance study. J Nucl Cardiol. 2023; 30(6):2607-2614. DOI: 10.1007/s12350-023-03256-w. View

20.

Miller R, Pieszko K, Shanbhag A, Feher A, Lemley M, Killekar A . Deep Learning Coronary Artery Calcium Scores from SPECT/CT Attenuation Maps Improve Prediction of Major Adverse Cardiac Events. J Nucl Med. 2022; 64(4):652-658. PMC: 10071789. DOI: 10.2967/jnumed.122.264423. View